Parters Vii L Pblair James ... Net Worth

The estimated Net Worth of Parters Vii L Pblair James ... is at least $4.68 million dollars as of 6 August 2019. Parters James owns over 250,000 units of Obalon Therapeutics Inc stock worth over $2,253,209 and over the last 9 years Parters sold OBLN stock worth over $2,426,402.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Parters James OBLN stock SEC Form 4 insiders trading

Parters has made over 8 trades of the Obalon Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Parters bought 250,000 units of OBLN stock worth $1,000,000 on 6 August 2019.

The largest trade Parters's ever made was buying 1,648,359 units of Obalon Therapeutics Inc stock on 23 August 2018 worth over $3,000,013. On average, Parters trades about 266,156 units every 135 days since 2016. As of 6 August 2019 Parters still owns at least 813,433 units of Obalon Therapeutics Inc stock.

You can see the complete history of Parters James stock trades at the bottom of the page.

Insiders trading at Obalon Therapeutics Inc

Over the last 8 years, insiders at Obalon Therapeutics Inc have traded over $0 worth of Obalon Therapeutics Inc stock and bought 3,260,355 units worth $6,939,913 . The most active insiders traders include Parters Vii L Pblair James ..., Partners X Lp Inter West Ma... et David Moatazedi. On average, Obalon Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $432,771. The most recent stock trade was executed by William J. Plovanic on 12 November 2019, trading 65,000 units of OBLN stock currently worth $107,900.

What does Obalon Therapeutics Inc do?

Obalon Therapeutics, Inc. is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.

Complete history of Parters James stock trades at Evoke Pharma Inc et Obalon Therapeutics Inc

Obalon Therapeutics Inc executives and stock owners

Obalon Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Kelly Huang Ph.D.,
  Consultant
• Andrew Rasdal,
  Chairman of the Board, President, Chief Executive Officer
• Andrew P. Rasdal,
  CEO, Pres & Director
• Sharon Stevenson,
  Independent Director
• Lesley Howe,
  Independent Director
• Douglas Fisher,
  Independent Director
• Raymond Dittamore,
  Independent Director
• William Plovanic,
  Director
• Robert MacDonald,
  Chief Retail Officer
• Donald Young,
  Vice President of Quality Assurance
• Todd Wood,
  Vice President - Global Sales
• Lisa Metzner,
  Vice President of Marketing
• Matthew Norwood,
  Vice President of Sales
• Steve Johnson,
  Vice President - Operations
• Nooshin Hussainy,
  Chief Financial Officer
• Nooshin Hussainy,
  CFO & Sec.
• Kim P. Kamdar,
  
• Erin Morisey,
  VP Strategic Partnerships
• Partners X Lp Inter West Ma...,
  
• David Moatazedi,
  
• Vii Associates Lpblair Jame...,
  
• Parters Vii L Pblair James ...,
  
• Amy Vanden Berg,
  Chief Clinical & Reg Officer
• Kelly Huang,
  Pres & Chief Executive Officer
• Robert H Jr Mondore,
  VP of Operations
• Jonah Shacknai,
  
• Partners X Lp Inter West Ma...,
  
• Daina Schmidt,
  Vice President of Marketing
• Mark Brister,
  Chief Technology Officer